Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Willow Biosciences Inc T.WLLW

Alternate Symbol(s):  CANSF

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.


TSX:WLLW - Post by User

Comment by Scotty007on Jan 20, 2021 8:15am
187 Views
Post# 32331906

RE:RE:Willow Biosciences Looks To Launch Biosynthesized THC In Can

RE:RE:Willow Biosciences Looks To Launch Biosynthesized THC In CanNot avoiding the CBD market, just navigating the compliance issues. Willow can produce a much cheaper, cleaner, and faster CBD product but the current law is restrictive.
The FDA approved Epidiolex (Cannabidiol) for GW Pharmaceuticals in 2018 who are looking to protect their market position while the use of CBD is classified as a controlled substance in the US.
This is one reason why Willow have pursued CBG as it will prove to be less problematic in a compliance sense than CBD products. CBG is also the precursor for CBD and THC. CBG may have similar properties to CBD and has not been classified as a controlled substance in the US.
<< Previous
Bullboard Posts
Next >>